Mizuho Initiates Coverage On Athira Pharma with Buy Rating, Announces Price Target of $6
Mizuho analyst Graig Suvannavejh initiates coverage on Athira Pharma (NASDAQ:ATHA) with a Buy rating and announces Price Target of $6.
Mizuho Initiates Coverage On Alector with Buy Rating, Announces Price Target of $15
Mizuho analyst Graig Suvannavejh initiates coverage on Alector (NASDAQ:ALEC) with a Buy rating and announces Price Target of $15.
Wells Fargo Downgrades Bank OZK to Equal-Weight, Lowers Price Target to $42
Wells Fargo analyst Jared Shaw downgrades Bank OZK (NASDAQ:OZK) from Overweight to Equal-Weight and lowers the price target from $58 to $42.
Jefferies Downgrades Applied Molecular to Hold
Jefferies analyst Chris Howerton downgrades Applied Molecular (NASDAQ:AMTI) from Buy to Hold.
Mizuho Initiates Coverage On Cerevel Therapeutics Hldg with Neutral Rating, Announces Price Target of $30
Mizuho analyst Graig Suvannavejh initiates coverage on Cerevel Therapeutics Hldg (NASDAQ:CERE) with a Neutral rating and announces Price Target of $30.
Mizuho Initiates Coverage On Harmony Biosciences with Buy Rating, Announces Price Target of $64
Mizuho analyst Graig Suvannavejh initiates coverage on Harmony Biosciences (NASDAQ:HRMY) with a Buy rating and announces Price Target of $64.
Jefferies Upgrades Tenaris to Buy, Raises Price Target to $46
Jefferies analyst Alan Spence upgrades Tenaris (NYSE:TS) from Hold to Buy and raises the price target from $35.7 to $46.
Mizuho Downgrades CytomX Therapeutics to Neutral, Lowers Price Target to $4
Mizuho analyst Mara Goldstein downgrades CytomX Therapeutics (NASDAQ:CTMX) from Buy to Neutral and lowers the price target from $16 to $4.
What 7 Analyst Ratings Have To Say About Voya Financial
Over the past 3 months, 7 analysts have published their opinion on Voya Financial (NYSE:VOYA) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
Why Mercer Shares Are Surging Today
Credit Suisse analyst Andrew M. Kuske upgraded Mercer International Inc. (NASDAQ:MERC) to Outperform from Neutral and raised the price target to $19 (an…